Biovest International Inc.(fka BVTIQ)

[mlkrborn]

Biovest eligibility to seek EU Marketing Approval for its BiovaxID Cancer Vaccine as Orphan Drug confirmed by EMA (BVTI) 0.40 +0.03 : Biovest International, majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (ABPI), announced that in response to Biovest's notice of intent to file for marketing approval previously submitted to the European Medicines Agency (EMA), the EMA has provided formal notification that Biovest is eligible to submit its planned Marketing Authorization Application (MAA) for BiovaxID under the EMA's centralized procedure as an orphan medicinal product for the treatment of follicular non-Hodgkin's lymphoma. Upon approval, BiovaxID would be the first cancer vaccine available in Europe for lymphoma patients.